As it turned out, adding spartalizumab to treatment with the two targeted drugs failed to provide ... to market well behind other PD-1/PD-L1 checkpoint inhibitors – that piggybacking on its ...

Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category ... in its cancer pipeline. CDK2 drug shows promise Those include potential first-in-class CDK2 inhibitor INCB123667, which ...

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no ...

Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...

Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); ...

"Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours" was originally created and published by ...